engleski

Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017

Recent developments in the diagnosis and treatment of chronic lymphocytic leukemia (B- CLL) have led to change of approach in clinical practice. New treatments have been approved based on the results of randomized multicenter trials for fi rst line and for salvage therapy, and the results of numerous ongoing clinical trials are permanently providing new answers and further refi ning of therapeutic strategies. Th is is paralleled by substantial increase in understanding the disease genetics due to major advances in the next generation sequencing (NGS) technology. We defi ne current position of the Croatian Cooperative Group for Hematologic Disease on diagnosis and treatment of CLL in the transition from chemo- immunotherapy paradigm into a new one that is based on new diagnostic stratifi cation and unprecedented therapeutic results of B-cell receptor inhibitors (BRI) and Bcl-2 antagonists. Th is is a rapidly evolving fi eld as a great number of ongoing clinical trials constantly accumulate and provide new knowledge. We believe that novel therapy research including genomic diagnosis is likely to off er new options that will eventually lead to time limited therapies without chemotherapy and more eff ective clinical care for B-CLL based on individualized precision medicine.

Chronic lymphocytic leukemia ; Practice guidelines as topic ; Precision medicine ; Croatia ; KROHEM

nije evidentirano